EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LUGANO in mid-2026 with LUCIA data to closely follow – WATERTOWN, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the independent Data Safety Monitoring Committee (DSMC) completed its second scheduled review of the Company's ongoing pivotal Phase 3 program evaluating DURAVYU for the treatment of wet age-related macular degeneration (wet AMD).

GlobeNewsWire • Nov 19, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

GlobeNewsWire • Nov 17, 2025

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. ( EYPT ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning. My name is Antoine, and I will be your conference operator today.

Seeking Alpha • Nov 5, 2025

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –

GlobeNewsWire • Nov 5, 2025

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.54 per share a year ago.

Zacks Investment Research • Nov 5, 2025

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Guggenheim's 2 nd Annual Healthcare Innovation Conference Forum: Fireside ChatDate: Monday, November 10, 2025Time: 10:30 a.m.

GlobeNewsWire • Nov 3, 2025

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments.

GlobeNewsWire • Oct 29, 2025

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first patient dosing, anticipated in the first quarter of 2026.

Benzinga • Oct 15, 2025

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 –

GlobeNewsWire • Oct 14, 2025

EyePoint Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. All of the shares are being offered by EyePoint. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $22.5 million of shares of EyePoint's common stock at the public offering price, less the underwriting discount.

GlobeNewsWire • Oct 14, 2025